Dihydroergotamine Mesylate Spray
Product Images NDC 72888-096

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Dihydroergotamine Mesylate (NDC 72888-096). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advagen Pharma Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dihydroergotamine Mesylate Nasal Spray (NDC 72888­096-19)

Packaging label for Dihydroergotamine Mesylate nasal spray, 4 mg/mL (1 mL/Vial), by Advagen Pharma Ltd. The label includes kit contents listing 8 vials and 8 nasal sprayers, administration instructions, and package insert. It also states the product is for nasal use only, not for injection, and provides storage instructions. Distributed by Advagen Pharma Limited, manufactured in Milan, Italy.*

FDA Label Image

Dihydroergotamine Mesylate Nasal Spray (NDC 72888­096-34)

Packaging label for Dihydroergotamine Mesylate nasal spray, 4 mg/mL strength, distributed by Advagen Pharma Limited and manufactured by Mipharm, S.p.A. The label states it includes 1 vial and 1 sprayer. The label specifies the product is for nasal use only, not for injection, and provides additional information about contents, storage, and migraine therapy instructions.*

FDA Label Image

Dihydroergotamine Mesylate Nasal Spray (NDC 72888­096-18)

Label for Dihydroergotamine Mesylate Nasal Spray, 4 mg/mL (1 mL per vial), distributed by Advagen Pharma Limited and manufactured by Mipharm, S.p.A. The label specifies nasal use only, not for injection, and includes the NDC 72888-096-18 along with distributor and manufacturer information and a barcode.*

FDA Label Image

Image Description (Dihydroergotamine Mesylate Nasal Spray Figure 1)

A line graph showing the estimated probability of patient response within four hours after a single 2 mg dose of dihydroergotamine mesylate nasal spray versus placebo. The x-axis represents time from first dose in hours, and the y-axis shows the estimated probability of response in percentage. The graph compares responses from 208 treated patients and 200 placebo patients, indicating higher response rates for the nasal spray over time.*

FDA Label Image

Image Description (Dihydroergotamine Mesylate Nasal Spray Figure 2)

A line graph titled 'Estimated Probability of a Patient Responding to dihydroergotamine mesylate Nasal Spray During the Four Hours Following Dosing.' It compares response probabilities over time (0 to 4 hours) between Dihydroergotamine mesylate Nasal Spray and placebo groups, with the spray showing higher probabilities increasing up to about 50% at 4 hours, while placebo remains lower around 30%. The graph is from Studies 3 and 4, with sample sizes N=97 for spray and N=100 for placebo.*

FDA Label Image

Image Description (Dihydroergotamine Mesylate Nasal Spray Figure 3)

A line graph showing the estimated probability of patients using additional treatments for migraine over 24 hours following administration of dihydroergotamine mesylate nasal spray 2 mg versus placebo. The y-axis represents the estimated probability of analgesic use from 0% to 100%, and the x-axis shows time in hours after the first spray from 0 to 24 hours. Two curves compare the treatment (lower curve) and placebo (higher curve) groups over time.*

FDA Label Image

Dihydroergotamine Mesylate Nasal Spray (NDC 72888­096-18)

Packaging label for Dihydroergotamine Mesylate nasal spray, 4 mg/mL strength, containing 1 vial and 1 sprayer. The label indicates the product is Rx only, not for individual sale, and for nasal use only, not for injection. Manufactured by Mipharm S.p.A, Italy and distributed by Advagen Pharma Limited, USA. Includes storage instructions and a barcode.*

FDA Label Image

Image Description (Dihydroergotamine Mesylate Nasal Spray Structure)

Chemical structure diagram of dihydroergotamine mesylate, showing its molecular formula (C33H37N5O5•CH4O3S) and molecular weight of 679.80.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.